These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30760409)
1. Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis from rare etiologies. Mah M; Mack LA; Hurton S; Bouchard-Fortier A Am J Surg; 2019 May; 217(5):923-927. PubMed ID: 30760409 [TBL] [Abstract][Full Text] [Related]
2. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640 [TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
4. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ihemelandu C; Bijelic L; Sugarbaker PH Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250 [TBL] [Abstract][Full Text] [Related]
5. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases. Kyang LS; Alzahrani NA; Valle SJ; Rahman MK; Arrowaili A; Liauw W; Morris DL J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588 [TBL] [Abstract][Full Text] [Related]
6. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. Passot G; Vaudoyer D; Villeneuve L; Kepenekian V; Beaujard AC; Bakrin N; Cotte E; Gilly FN; Glehen O J Surg Oncol; 2016 Jun; 113(7):796-803. PubMed ID: 27110915 [TBL] [Abstract][Full Text] [Related]
7. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center. Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164 [TBL] [Abstract][Full Text] [Related]
9. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
10. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma. Saxena A; Valle SJ; Liauw W; Morris DL Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894 [TBL] [Abstract][Full Text] [Related]
11. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450 [TBL] [Abstract][Full Text] [Related]
12. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929 [TBL] [Abstract][Full Text] [Related]
13. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250 [TBL] [Abstract][Full Text] [Related]
14. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852 [TBL] [Abstract][Full Text] [Related]
15. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. Lee L; Alie-Cusson F; Dubé P; Sideris L J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831 [TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. Iversen LH; Rasmussen PC; Hagemann-Madsen R; Laurberg S Colorectal Dis; 2013 Jul; 15(7):e365-72. PubMed ID: 23458368 [TBL] [Abstract][Full Text] [Related]
17. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467 [TBL] [Abstract][Full Text] [Related]
18. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834 [TBL] [Abstract][Full Text] [Related]
19. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754 [TBL] [Abstract][Full Text] [Related]
20. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis. Bekhor E; Carr J; Hofstedt M; Sullivan B; Solomon D; Leigh N; Bolton N; Golas B; Sarpel U; Labow D; Magge D Ann Surg Oncol; 2020 May; 27(5):1448-1455. PubMed ID: 31873928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]